TGF-β1 Negatively Regulates the Number and Function of Hematopoietic Stem Cells

Xiaofang Wang,1 Fang Dong,1 Sen Zhang,1 Wanzhu Yang,1 Wenying Yu,1 Zhao Wang,1 Shanshan Zhang,1 Jinhong Wang,1 Shihui Ma,1 Peng Wu,1 Yun Gao,2 Ji Dong,2 Fuchou Tang,2 Tao Cheng,1 and Hideo Ema1,∗

1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing Road 288, Tianjin 300020, China
2Biodynamic Optical Imaging Center, College of Life Sciences, Peking University, Beijing 100871, China
*Correspondence: hema@ihcams.ac.cn
https://doi.org/10.1016/j.stemcr.2018.05.017

SUMMARY

Transforming growth factor β1 (TGF-β1) plays a role in the maintenance of quiescent hematopoietic stem cells (HSCs) in vivo. We asked whether TGF-β1 controls the cell cycle status of HSCs in vitro to enhance the reconstitution activity. To examine the effect of TGF-β1 on the HSC function, we used an in vitro culture system in which single HSCs divide with the retention of their short- and long-term reconstitution ability. Extensive single-cell analyses showed that, regardless of its concentration, TGF-β1 slowed down the cell cycle progression of HSCs but consequently suppressed their self-renewal potential. Cycling HSCs were not able to go back to quiescence with TGF-β1. This study revealed a negative role of TGF-β1 in the regulation of the HSC number and reconstitution activity.

INTRODUCTION

Hematopoietic stem cells (HSCs) have the potential of self-renewal and differentiation into all blood lineages (Seita and Weissman, 2010). Since their self-renewal potential is finite (Ema et al., 2005), adult HSCs stay in a quiescent state most of the time (Sun et al., 2014) and undergo self-renewal divisions only four times in the lifespan of a mouse (Bernitz et al., 2016), preventing them from exhaustion. Quiescence is an important property of HSCs, but how HSCs maintain the quiescent state and how cycling HSCs return to the quiescent state is poorly understood.

Transforming growth factor β1 (TGF-β1) is a candidate cytokine that regulates quiescent HSCs in the bone marrow niche (Sitnicka et al., 1996; Yamazaki et al., 2007, 2011; Zhao et al., 2014). TGF-β1 activates Smad/FoxO signaling (Seoane et al., 2004), which is required for the maintenance of the HSC pool (Karlsson et al., 2007; Miyamoto et al., 2010; Muller-Sieburg et al., 2002; Yamamoto et al., 2013). In the mouse, HSC subsets are classified as myeloid-biased, balanced, and lymphoid-biased HSCs (Cho et al., 2008; Muller-Sieburg et al., 2002, 2004). It was recently reported that TGF-β1 at a low concentration stimulates the proliferation of myeloid-biased HSCs but inhibits that of lymphoid-biased HSCs (Challen et al., 2010). In this study, we used transplantation assays to examine the effects of different concentrations of TGF-β1 on long-term (LT, >6 months) and short-term (ST, <6 months) HSCs, in which myeloid-biased HSCs and lymphoid-biased HSCs are enriched (Ema et al., 2014).

To overcome the problem of heterogeneity in the HSC population, we used single-cell culture, single-cell transplantation, and single-cell PCR to examine the direct effect of TGF-β1 on single HSCs. Here, we report that although TGF-β1 slowed down the cell cycle progression in HSCs, the self-renewal potential in both the LT- and ST-HSCs was reduced. Thus, we propose that TGF-β1 is a negative regulator of the number and reconstitution activity of HSCs that have entered the cell cycle (cycling HSCs).

RESULTS

Single-Cell RT-PCR

We defined CD150+/CD34− c-Kit+Sca-1+ Lineage− (KSL) cells as the HSC1 population (Figure S1A). TGF-β1 binds to the receptor consisting of TGFBR1 and TGFBR2 (Massague, 1998). We performed a single-cell
Figure 1. Gene Expression in Single HSCs
Forty-eight single HSC1 cells were sorted by flow cytometry (fresh cells). Forty-eight single HSC1 cells were cultured in SCF + TPO for 24 hr (cultured cells). RT-PCR was performed on these single cells to compare the expression of the 48 genes.

(legend continued on next page)
gene expression analysis of freshly isolated HSC1 cells and cultured single cells. Single HSC1 cells were cultured in the presence of SCF + TPO for 24 hr. The cells that remained as single cells after culture were selected. The expression of 48 genes was examined for 48 single cells (Table S1). Gapdh and Actb were included as controls.

The gene expression data are shown in a heatmap format in Figure S1B. Figure 1A shows the percentage of gene-expressing cells (percentage positive cells, threshold cycle values [Ct] < 27.65). Figure 1B shows the violin plots of the relative gene expression level in the positive cells. Gapdh, Actb, c-Kit, and c-Mpl were detected in most cells. In the freshly isolated HSC1 cells, only six of the 48 cells (12.5%) expressed Tgfbr1. However, after 24 hr in culture, 21 of the 48 cells (43.8%) expressed Tgfbr1. The relative expression of Tgfbr1 was similar between the freshly isolated cells and the cultured cells. In the freshly isolated HSC1 cells, 27 of the 48 cells (56.3%) expressed Tgfbr2, and 38 of the 48 cells (79.2%) expressed Tgfbr3. The number of Tgfbr2- and Tgfbr3-positive cells did not change after culture. However, the relative expression of Tgfbr2 and Tgfbr3 became significantly higher after culture. Most importantly, both Tgfbr1 and Tgfbr2 were expressed in only 1 of 48 cells (2.1%) before culture and 16 of 48 cells (33.3%) after culture. Other cytokine receptor genes, with the exception of Csf2rb, IL-12rb1, and IL-12rb2, did not change in either the percentage of positive cells or the relative expression.

Mki67, a marker of proliferation, was dramatically increased after culture in both the percentage of positive cells and the relative expression. Similarly, Ccne1, Ccne2, and Cdk1 increased after culture in both the percentage of positive cells and the relative expression. Interestingly, Cdkn1b and Ccnd2 were already expressed in the freshly isolated cells. These data showed that upregulation of the TGF-β1 receptor was associated with cell cycle progression in HSCs.

**Titration of TGF-β1 by In Vitro and In Vivo Assays**

We next examined the dose effect of TGF-β1 on HSC1 cells by in vitro single-cell culture. Single HSC1 cells were directly sorted into 96-well plates containing SF-O3 serum-free medium with SCF + TPO in the presence or absence of human TGF-β1 at different concentrations, as follows: 0 and 0.1 pg/mL; 1, 10, and 100 pg/mL; 1 and 10 ng/mL. Based on the number of cells per well from each day of culture, the cell division kinetics were estimated (Figure S2A). Figure S2B shows the data. The first, second, and third divisions were similar between SCF + TPO and SCF + TPO + TGF-β1 cultures at 0, 0.1, 1, and 10 pg/mL of TGF-β1. In contrast, the second and third divisions slowed down in the SCF + TPO + TGF-β1 culture at 100 pg/mL, 1 ng/mL, and 10 ng/mL of TGF-β1. Figure 2A shows the number of cells per well on day 5 of culture. Without TGF-β1, the number of cells per well was 17.9 ± 1.43 (mean ± SD, n = 180). The numbers of cells per well with TGF-β1 at concentrations of 0.1 pg/mL, 1 pg/mL, 10 pg/mL, 100 pg/mL, 1 ng/mL, and 10 ng/mL were 19.2 ± 1.33, 22.0 ± 1.6, 13.2 ± 0.7, 37.7 ± 0.2, 2.5 ± 0.2, and 2.6 ± 0.1, respectively (mean ± SD, n = 180 in each culture). The number of cells in culture with 10 pg/mL of TGF-β1 was significantly smaller than those in culture with 0.1 pg/mL and 1 pg/mL of TGF-β1 (p = 0.0026) and was significantly larger than those in culture with 100 pg/mL, 1 ng/mL, and 10 ng/mL of TGF-β1 (p < 0.0001). These data showed that 100 pg/mL of TGF-β1 was sufficient for the in vitro suppression of HSC proliferation. The representative pictures of day 7 colonies from each concentration of TGF-β1 are shown in Figure S2C.

We also examined the dose effect of TGF-β1 on HSC1 cells using an in vivo repopulating assay. Ten HSC1 cells were sorted and injected into lethally irradiated mice along with competitor cells. Ten HSC1 cells were also cultured with SCF, TPO, and TGF-β1 at concentrations of 0, 10, and 100 pg/mL and 1 and 10 ng/mL for 5 days and were similarly transplanted. To detect repopulation by the test donor cells, peripheral blood was examined from 1 month to 12 months after transplantation. Figure 2B shows that the recipient mice transplanted with 10 freshly isolated HSC1 cells showed varying degrees of donor cell repopulation. The same was true for recipient mice transplanted with 10 HSC1 cells that were cultured with SCF + TPO for 5 days. After culture with SCF + TPO for 5 days, the ST reconstitution levels (1, 2, and 4 months after transplantation) were significantly greater than those in the freshly isolated cells (p = 0.026). ST reconstitution levels (1, 2, and 4 months after transplantation) in the cells cultured with 10 pg/mL of TGF-β1 were significantly greater than those in the cells cultured with 100 pg/mL, 1 ng/mL, and 10 ng/mL of TGF-β1 (p < 0.001) but were not greater than those in the cells cultured without TGF-β1. LT reconstitution levels (6, 8, 10, and 12 months after transplantation) in the cells cultured with 10 pg/mL of TGF-β1 were significantly lower than those in the cells cultured without TGF-β1 (p = 0.006) but not lower than those in the cells
cultured with 100 pg/mL, 1 ng/mL, and 10 ng/mL of TGF-β1. These data showed that 100 pg/mL of TGF-β1 was sufficient for the suppression of ST and LT reconstitution activity. Interestingly, 10 pg/mL of TGF-β1 suppressed LT but not ST reconstitution activity in HSCs. From these in vitro and in vivo titration data, we decided to use 100 pg/mL of TGF-β1 for the rest of the study.

**Early Cell Division Kinetics of HSC1 Cells in the Presence of TGF-β1**

We performed single-cell cultures with the HSC1 cells. **Figure 3A** shows the first, second, and third divisions of the HSC1 cells in the presence of SCF + TPO or SCF + TPO + TGF-β1. On average, 80.0% of the HSC1 cells underwent the first, second, and third divisions in the presence of SCF + TPO, showing that the cells continuously and rapidly divided. However, 76.7%, 50.0%, and 33.3% of the HSC1 cells underwent the first, second, and third division in the presence of SCF + TPO + TGF-β1. The division kinetics curves were significantly shifted to the right in the second and third divisions in the presence of SCF + TPO + TGF-β1, compared with those in the presence of SCF + TPO. These data showed that the cells slowly divided and that a portion of the cells stopped dividing in the presence of TGF-β1.

**Figure 3B** shows the number of cells per well for each of the cultures. The cell number in the SCF + TPO cultures was significantly lower than for those in culture with 0 pg/mL of TGF-β1 (**p = 0.0026) and was significantly larger than for those in culture with 100 pg/mL, 1 ng/mL, and 10 ng/mL of TGF-β1 (**p < 0.001). The numbers of cells in culture with 0, 0.1, and 1 pg/mL of TGF-β1 or 100 pg/mL, 1 ng/mL, and 10 ng/mL of TGF-β1 were not significantly different (ANOVA). NS, not significant.

See also **Figure S2**.
increased exponentially from day 1 to day 7. However, the cell number in the SCF + TPO + TGF-β1 cultures slightly increased until day 4. To compare the cell division dynamics between cultures with SCF + TPO and SCF + TPO + TGF-β1, the cells were classified into three groups as follows: quiescent cells (one cell per well throughout the culture period), transiently dividing cells (an increase and then a decrease in cell number during the culture period), and continuously dividing cells (a continuous increase in cell number during the culture period). The percentages of the classified cells are shown. The wells without cells were excluded from the analysis. (B and C) A total of 238 wells from five independent experiments were analyzed for SCF + TPO and a total of 245 wells from five independent experiments were analyzed for SCF + TPO + TGF-β1.

Figure 3. Single-Cell Culture of HSCs with TGF-β1
(A) Early division kinetics of HSC1 cells. Sixty single HSC1 cells were cultured with SCF + TPO or SCF + TPO + TGF-β1 for 7 days. The cumulative numbers of cells per 60 cells are shown for the first, second, and third divisions.

(B) The table shows the number of cells per well on days 1–7. Sixty single HSC1 cells were cultured in the presence of SCF + TPO with or without TGF-β1. The cell numbers in the SCF + TPO cultures were significantly greater than those in the SCF + TPO + TGF-β1 cultures on days 2–7. **p < 0.01; ***p < 0.001 (unpaired t test). The wells without cells were excluded from the analysis. (A and B) Data are shown as mean ± SD from five independent experiments.

(C) The cells were classified into three categories as follows: quiescent cells (one cell per well throughout the culture period), transiently dividing cells (an increase and then a decrease in cell number during the culture period), and continuously dividing cells (a continuous increase in cell number during the culture period). The percentages of the classified cells are shown. The wells without cells were excluded from the analysis. (B and C) A total of 238 wells from five independent experiments were analyzed for SCF + TPO and a total of 245 wells from five independent experiments were analyzed for SCF + TPO + TGF-β1.
We evaluated the effect of TGF-β1 on dividing HSC1 cells at different time periods using an in vivo repopulating assay. Ten HSC1 cells were sorted and injected into lethally irradiated mice along with competitor cells. Ten HSC1 cells were also cultured with SCF + TPO as controls and SCF + TPO+100 pg/mL of TGF-β1 for 3, 5, or 7 days and were then similarly transplanted. To detect repopulation by the test donor cells, the peripheral blood was examined from 1 month to 12 months after transplantation. 

Figure 4A shows that the recipient mice transplanted with 10 freshly isolated HSC1 cells showed donor cell repopulation. The same was found for recipient mice transplanted with 10 HSC1 cells that were cultured with SCF + TPO for 3, 5, or 7 days. After culture with SCF + TPO for 3, 5, or 7 days, the ST and LT reconstitution levels were comparable with those of the freshly isolated cells. In contrast, ST and LT reconstitution levels in the cells cultured with TGF-β1 were significantly lower than those in the cells cultured with SCF + TPO (p < 0.001). The reconstitution levels in the cells cultured with TGF-β1 for 7 days were significantly lower than those in the cells cultured with TGF-β1 for 3 or 5 days (p < 0.001). These data showed that TGF-β1 reduced not only ST reconstitution but also LT reconstitution from the early to late phases of culture.

We next examined the effect of a delayed addition of TGF-β1 on cell division in the single-cell culture. Figure S3A shows that when TGF-β1 was added to cultures at day 0, the number of cells that underwent second and third divisions was reduced, and these divisions occurred slowly. When TGF-β1 was added to cultures at day 3, the number of third divisions was reduced. When TGF-β1 was added to cultures at day 5, most of the cells had gone through these divisions, and we did not see any effect on these divisions. Figure S3B shows the number of cells per well at day 7. The number of cells with TGF-β1 from days 0 and 3, but not from day 5, were significantly different from those without TGF-β1.

We then examined the effect of a delayed addition of TGF-β1 on the reconstitution activity in HSC1 cells. Ten HSC1 cells were sorted and injected into lethally irradiated mice along with competitor cells. Ten HSC1 cells were also cultured with SCF + TPO as a control, and TGF-β1 was added into the medium at day 0, 3, or 5 of culture. On day 7 of culture, the cells were transplanted. To detect repopulation by the test donor cells, the peripheral blood was examined from 1 month to 12 months after transplantation. Figure 4B shows that all the recipient mice transplanted with 10 freshly isolated HSC1 cells showed donor cell repopulation. The same was true for those transplanted with 10 HSC1 cells cultured with SCF + TPO for 7 days. Regardless of the day of the TGF-β1 addition, the ST and LT reconstitution levels were all significantly reduced (p < 0.001). Interestingly, only the last 2 days of exposure were sufficient to make this reduction. These data suggested that, in the last 2 days of culture, the cells were more sensitive to TGF-β1.

TGF-β1 Reduces the Reconstitution Activity in Single HSC1s

In the dose response experiment, we showed that TGF-β1 at 10 pg/mL reduced only the LT reconstitution ability and at 100 pg/mL reduced both the ST and LT reconstitution ability in the culture cells. To verify these findings, we examined the ability of cells derived from single HSC1 cells in culture at 10 and 100 pg/mL of TGF-β1. As illustrated in Figure 5A, single HSC1 cells were transplanted into lethally irradiated recipient mice along with 5 × 10^5 competitor cells. The single HSC1 cells were cultured in SCF, TPO, and TGF-β1 (0, 10, or 100 pg/mL) for 5 days and were then transplanted into lethally irradiated mice.

As shown in Figure 5B, the frequencies of the reconstitution were 36.7% for the freshly isolated HSC1 cells (11/30 mice), 36.7% for the SCF + TPO cultured cells (11/30 mice), 23.3% for the SCF + TPO+10 pg/mL TGF-β1 cultured cells (7/30 mice), and 13.3% for SCF + TPO+100 pg/mL TGF-β1 cultured cells (4/30 mice). There were eight LT-HSCs and three ST-HSCs detected in the fresh group. Six LT-HSCs and five ST-HSCs were detected in the SCF + TPO group. No LT-HSCs, but one ST-HSC and six B lymphoid progenitors were detected in the 10 pg/mL TGF-β1 culture. Neither the LT-HSCs nor the ST-HSCs were detected in the 100 pg/mL TGF-β1 culture. Four B lymphoid progenitors were detected in this group. Consistent with the in vivo dose response data, the LT-HSCs were more sensitive than the ST-HSCs in clonal transplantation. Taken together, both the LT and ST reconstitution and the myeloid and T
lymphoid lineage differentiation potentials were markedly reduced by TGF-β1.

**Gene Expression Analysis of Slowly Cycling Cells with TGF-β1**

We wished to see the effect of TGF-β1 on the expression of cytokine receptors and cell cycle regulators in cultured cells. Single HSC1 cells were cultured in serum-free media with SCF + TPO or SCF + TPO + TGF-β1 for 48 and 120 hr. One cell was picked from each of the 48 wells and subjected to single-cell RT-PCR. As shown in Figures 6A and S4A, the percentages of gene-expressing cells for Kit, Mpl, Tgfb1, Tgfb2, and Tgfb3 were similar at 48 and 120 hr after culture between the SCF + TPO and SCF + TPO + TGF-β1 cultures. As shown in Figures 6B and S4B, the percentages of gene-expressing cells for Ccdn2, Ccdn3, Ccne1, Ccne2, Cdk1, Cdk4, and Mki67 were similar at 48 and 120 hr after culture between the SCF + TPO and
Figure 5. TGF-β1 at Concentrations of 10 and 100 pg/mL Reduces the Total and Myeloid Reconstitution Levels in a Single-Cell Culture

(A) Single HSC1 cells, sorted from the BM cells of the B6-Ly5.1 mice, were transplanted into 30 lethally irradiated B6-Ly5.2 mice with $5 \times 10^5$ competitor cells from the B6-Ly5.2 mice. The single cells were also cultured in serum-free medium with SCF + TPO or SCF + TPO + TGF-β1 (10 or 100 pg/mL) for 5 days and were then transplanted into 30 lethally irradiated B6-Ly5.2 mice with $5 \times 10^5$ competitor cells from the B6-Ly5.2 mice.

(B) Clonal cell transplantation. The percentage of chimerism in the granulocytes/monocytes, B cells, and T cells of the peripheral blood was analyzed 1, 3, 6, 10, and 12 days after transplantation. Two separate cohorts of single-cell transplantation experiments were performed, but the data from one experiment are shown. Individual mice were identified by numbering.
SCF + TPO + TGF-β1 cultures. To confirm that these data represented cultured cells, 48 single cells were picked from a colony consisting of 56 cells in the SCF + TPO culture, and 8, 20, and 20 single cells were picked from colonies consisting of 8, 20, and 26 cells, respectively, in the SCF + TPO + TGF-β1 culture. Single-cell gene expression analysis showed similar data (data not shown). These data indicate that cells surviving in the presence of TGF-β1 remained in the cell cycle and expressed cytokine receptors.

Blockade of the Inhibitory Effect of TGF-β1
To rescue TGF-β1-treated cells in culture, a neutralizing antibody against TGF-β1 was used. Single HSC1 cells were cultured in SCF + TPO or SCF + TPO + TGF-β1 for 7 days. Anti-TGF-β1 neutralizing antibody was added to the culture on days 0, 1, 3, and 5. As shown in Figure 6C, the number of cells per well was similar to that in SCF + TPO when the antibody was added on day 0, showing a complete block of the effect of TGF-β1. When the antibody was added on days 1, 3, and 5, the numbers of cells per well were significantly greater than those in SCF + TPO + TGF-β1 on days 4–7, days 4–7, and days 6–7, respectively. These results suggested that the reduced cell division rate was reversible.

DISCUSSION

TGF-β signaling is mediated by the TGFBR1 and TGFBR2 complex, phosphorylating Smad2/Smad3 (Shi and Massague, 2003; ten Dijke and Hill, 2004). These receptor-regulated Smads bind to Smad4 and together translocate to the nucleus and regulate gene expression. TGFBR1, TGFBR2, Smad2 and Smad3, and Smad4 knockout mice all showed lethal inflammation disease mostly due to activated T cells (Billing et al., 2017; Karlsson et al., 2007; Larsson et al., 2003, 2005; Yamazaki et al., 2011). However, only TGFBR2 and Smad4 knockout mice showed a decrease in LT reconstitution activity (Karlsson et al., 2007; Yamazaki et al., 2011). These data suggested that TGF-β/Smad signaling differs between T cells and HSCs, and the signal pathways in HSCs are more complex than those in T cells. Together with our previous data, on average, 13.8% ± 2.8% (mean ± SD, n = 5) of the HSC1 cells expressed Tgfbr1, whereas 45.0% ± 7.8% of the HSC1 cells expressed Tgfbr2. These data are consistent with the quantitative RT-PCR data of CD34+ KSL cells (Utsugisawa et al., 2006). Notably, single-cell RT-PCR showed that only 6.7% ± 3.1% of the cells expressed both Tgfbr1 and Tgfbr2. During our single-cell culture, approximately 5% of the HSC1 cells were detected as single cells for 7 days (Figure 3C). These cells were likely to be in G0 phase, as previously reported (Yamazaki et al., 2009). After culture with SCF + TPO, 44% and 60% of the cells expressed Tgfbr1 and Tgfbr2, respectively. As a result, 33% of the cells expressed both receptors (Figure 1A). The first division of the HSC1 cells in the SCF + TPO culture was not affected by TGF-β1 (Figure 3A). The HSC1 cells were ready to respond to TGF-β1 from their second division. Time seemed to be required for HSC1 cells to upregulate the expression of Tgfbr1 and respond to TGF-β1. These data suggest that a small number of HSC1 cells express both receptors in vivo, but a cytokine storm, which may occur in severe inflammation, for instance after bone marrow transplantation, likely induces the expression of TGF-β1 receptors.

Our data suggested that Tgfbr1 is not expressed in the majority of HSCs in vivo. This might be a reason why no abnormal function of HSCs was found in the TGFBR1 knockout mouse (Larsson et al., 2005). We may consider the possibility that Tgfbr2 is expressed with an unidentified type 1 receptor. Alternatively, different signals may be involved in Smad4 activation to maintain or induce the quiescence in HSCs. If this were the case, other mechanisms for the regulation of quiescent HSCs should be identified.

TGF-β1 is a pleiotropic factor that has positive or negative effects on a variety of cells (Dybedal et al., 1997; Larsson and Karlsson, 2005). It is suggested that the effect of TGF-β1 differs depending on its concentrations (Challen...
et al., 2010; Kale and Vaidya, 2004). This study was the first to examine its dose response effects on HSCs by transplantation assays. Data from an in vitro single-cell culture and in vivo competitive repopulation assay (Figures 2A and 2B) consistently showed that 100 pg/mL of TGF-β1 was sufficient to exert its effect. This concentration was much lower than those in previous studies (Challen et al., 2010; Sitnicka et al., 1996; Soma et al., 1996; Wiesmann et al., 2000; Yamazaki et al., 2009). ST and LT reconstitution activities in the SCF + TPO culture were significantly reduced by 100 pg/mL of TGF-β1 (Figure 4), supporting the previous study (Soma et al., 1996; Wiesmann et al., 2000). We further confirmed this finding by single-cell transplantation. Single-cell transplantation has an advantage over bulk-cell transplantation to identify different types of HSCs. We wished to see the effect of TGF-β1 on individual ST- and LT-HSCs. Consistent with 10-cell transplantation data, we did not see any positive effect on either ST-HSC or LT-HSCs (myeloid-biased HSCs) by single-cell transplantation (Figure 5). These data suggested that the self-renewal potential was markedly reduced in HSCs. Our transplantation data did not support the data from in vitro colony assays (Challen et al., 2010). The effect of TGF-β1 on the in vivo reconstitution potential may simply differ from that of the in vitro colony formation.

In vivo and in vitro studies are equally important because an in vivo study is suitable for examining physiological effects, while an in vitro study is suitable for examining direct effects. Perhaps, it is extremely difficult to clarify the mechanisms by only an in vivo study. If data from in vivo and in vitro studies are consistent, the finding should be affirmative. In this study, we focused on the in vitro effect of TGF-β1 on HSCs. We used a serum-free culture system, which is essential for maintaining the self-renewal potential in HSCs. Then, we were able to examine the effect of TGF-β1 on HSCs. We believe that a similar effect should be seen in vivo, at least in certain circumstances.

The biological activity of TGF-β family members is regulated in a complex manner. We are far from understanding how and where TGF-β1 is produced, activated, and degraded in vivo. Another advantage of our in vitro study was that TGF-β1 could be tested at a range of low concentrations, such as 10 pg/mL to 10 ng/mL (Figures 2B and 5). It is difficult to examine the precise concentrations of TGF-β1 in vivo. If TGF-β1 regulates cycling HSCs in vivo as well, some HSCs may undergo cell cycle arrest and apoptosis during severe inflammation. It was reported that anti-TGF-β neutralizing antibody can enhance the hematopoietic recovery after 5-fluorouracil treatment or bone marrow transplantation in mice (Brenet et al., 2013). The authors of this paper claimed that anti-TGF-β1 antibody prevents HSCs from returning to the G0 state. The antibody may also have rescued HSCs from apoptosis in severe inflammation.

Cell cycle regulation plays a critical role in controlling HSC function (Pietras et al., 2011). TGF-β1 slowed down the cell cycle progression of HSC progeny (Figure 3). Some HSCs stopped dividing, which resulted in cell cycle arrest with the loss of LT-HSC and ST-HSC activities (Figures 4 and 5). In particular, these activities were promptly lost in the last 2 days during 7 days of culture. We assumed that the HSCs were losing their self-renewal potential during this period of time and that TGF-β1 enhanced this event. Analysis of the expression of cell cycle regulators in surviving cells on day 5 of culture with TGF-β1 showed that all cells were still cycling. The expression of cytokine receptors on these cells was not changed by TGF-β1. These cells rapidly divided again after TGF-β1 was blocked by the antibody. It was likely that cells that had died before day 5 of culture were not detected by these assays. Importantly, quiescent cells were not detected either.

Nevertheless, TGF-β1 negatively regulated cycling HSCs in culture with SCF + TPO. If the G0 phase is the status in which HSCs can maintain their potential, TGF-β1 does not seem to be an appropriate cytokine to inhibit cycling HSCs for the purpose of HSC maintenance. In this regard, the TGF-β1-induced cell cycle status in vitro differs from the G0 status in vivo. Supporting the first study of TGF-β1 as a negative regulator in hematopoiesis (Ohta et al., 1987), this work provides a revised view of the action of TGF-β1 on HSCs.

**EXPERIMENTAL PROCEDURES**

**Mice**

C57BL/6 mice congenic for the Ly5 locus (B6-Ly5.1) and C57BL/6 (B6-Ly5.2) mice were obtained from the animal facility of the State Key Laboratory of Experimental Hematology. The mice were housed in individual cages in a specific-pathogen-free-grade animal facility. All the experimental protocols were approved by the Animal Care and Use Committee of the Institute of Hematology and Blood Diseases Hospital.

**Flow Cytometry**

Bone marrow (BM) cells were harvested from the tibiae, femora, and pelvis in phosphate buffered solution supplemented with 2% fetal calf serum (HyClone, US). For staining, the BM cells were incubated with anti-c-Kit microbeads (catalog no. 13-0081-85), B220 (clone RA3-6B2, catalog no. 13-0081-85), CD4 (clone GK1.5, catalog no.13-0081-85), CD8 (clone 53–6.7, eBioscience), B220 (clone RA3-6B2), CD4 (clone GK1.5, catalog no. 13-0081-85), CD8 (clone 53–6.7, catalog no. 13-0081-85), B220 (clone RA3-6B2, catalog no. 13-0452-85), Mac-1 (clone M1/7, catalog no. 13-0112-85), Gr-1 (clone RB6–8C5, catalog no. 13-5931-85), Ter-119 (clone TER-119, catalog no. 13-5921-85); PE/cyanin7 (PE-cy7) conjugated anti-Sca-1 (clone D7, catalog no. 25-5981-82, eBioscience), APC-conjugated...
anti-c-Kit (clone 2B8, catalog no. 17-1171-82, eBioscience), FITC-conjugated anti-CD34 (clone RAM34, catalog no. 11-0341-85, eBioscience), PE-conjugated anti-CD150 (clone TC15-12F12.2, catalog no. 115904, BioLegend), and PerCP-eFluor710-conjugated anti-CD41 (clone MWReg30, catalog no. 46-0411-82, eBioscience) mAbs. The biotinylated mAbs were developed with APC/cyanin7 (APC-cy7)-conjugated streptavidin (catalog no. 47-4317-82, eBioscience). The cells were sorted on a FACS_Aria III cell sorter (BD Biosciences) under the single-cell sorting mode. CD150+CD41+CD34−KSL cells enriched in LT-HSCs (Yamamoto et al., 2013) were designated as HSC1 cells.

For the peripheral blood analysis, the mice were bled from the tail, the red blood cells were lysed with red blood cell lysis buffer, and the cells were incubated with the following antibodies on ice for 30 min: FITC-conjugated anti-CD45.1 (clone A20, catalog no. 11-0453-85), PE-conjugated anti-CD45.2 (clone 104, catalog no. 12-0454-82), PE/cyanin7 (PE-cy7)-conjugated anti-CD4 (clone GK1.5, catalog no. 12-0454-82), APC-conjugated anti-CD8 (clone 53–6.7, catalog no. 17-0081-82), PerC-cy5.5-conjugated anti-CD122 (clone RA3-6B2, catalog no. 45-0452-82), APC-eFluor780-conjugated anti-Mac-1 and Gr-1 (clone M1/70, catalog no. 47-0112-82 and clone RB6-8C5, catalog no. 47-5931-82), and DAPI, all purchased from eBioscience. The cells were then spun down and resuspended in a PBS solution, and the analysis was accomplished on live cells with an FACS Canto II system (Becton Dickinson, US).

**Single-Cell Culture**

Single HSC1 cells were deposited into 96-well microwell plates containing 200 μL of SF-O3 (Sanko Junyaku, Japan) supplemented with 5 × 10−5 M 2-β-mercaptoethanol, 0.5 mg/mL of recombinant human serum albumin (catalog no. 1001, Albumin Bioscience, Japan), 10 mM HEPES (catalog no. H0887, Sigma, US), 10 μM nonessential amino acids (catalog no. 11,140-050, Gibco, US), 50 U of penicillin/streptomycin (catalog no. 15,140-122, Life Technology, US), and 2 mM L-glutamine (catalog no. 25,030-081, Gibco, US) as a serum-free medium. Single HSC1 cells were cultured in serum-free media (Ieyasu et al., 2017). The cells were cultured in 50 ng/mL of SCF and 50 ng/mL of TPO with different concentrations (0, 0.1 μg/mL, 1 μg/mL, 10 pg/mL, 100 pg/mL, 1 ng/mL, and 10 ng/mL) of human TGF-β1 (PeproTech, US). The cells were cultured at 37°C with 5% CO₂ in the air. The number of cells per well was monitored daily by microscopy.

**Ten-Cell Transplantation**

Ten HSC1 cells were sorted from the BM cells of the B6-Ly5.1 mice and were injected into lethally irradiated B6-Ly5.2 mice with 5 × 10⁵ competitor cells from the B6-Ly5.2 mice. Ten HSC1 cells were sorted from the BM cells of the B6-Ly5.1 mice, were cultured in serum-free medium with SCF + TPO as a control or SCF + TPO + 100 pg/mL of TGF-β1 for 3–7 days, and were transplanted with 5 × 10⁵ competitor cells from the Ly5.2 mice into the lethally irradiated B6-Ly5.2 mice. The percentage of test donor cells (CD45.1+ cells) of granulocytes/monocytes, B cells, and T cells in the peripheral blood was analyzed 1, 2, 4, 6, 8, 10, and 12 months after the transplantation.

**Single-Cell Transplantation**

Single HSC1 cells, sorted from the BM cells of the B6-Ly5.1 mice, were transplanted into lethally irradiated B6-Ly5.2 mice with 5 × 10⁵ competitor cells from the B6-Ly5.2 mice. The single cells were also cultured in serum-free medium with SCF + TPO or SCF + TPO + TGF-β1 (10 or 100 pg/mL) for 5 days and were then transplanted. The percentage of test donor cells (CD45.1+ cells) in the granulocytes/monocytes, B cells, and T cells of the peripheral blood was analyzed 1, 3, 6, 8, 10, and 12 months after transplantation. LT-HSCs were defined by a myeloid lineage reconstitution for 6 months or more. Lymphoid lineage reconstitution may not be essential for LT-HSCs, as recently suggested (Carrelia et al., 2018). ST-HSCs were defined as myeloid lineage reconstitution for less than 6 months, with B and T lymphoid reconstitution at one time. When the percentage of CD45.1+ cells was greater than 0.1%, reconstitution was considered to have occurred (positive mouse).

**Single-Cell RT-PCR**

Single HSC1 cells were sorted into 48 wells of a 96-well plate where each well contained 10 μL of a reverse-transcription and specific-target amplification mixture (RT buffer) consisting of 2.5 μL of 0.2× primers, containing all 48 sets of primers (Table S1), 5.0 μL of a 2× reaction mix, 0.5 μL of Superscript III, and 2.0 μL of Tris-EDTA buffer. Single HSC1 cells were cultured in serum-free media with SCF + TPO for 24 hr. Single cells were identified under an inverted microscope and were picked up by a micromanipulator (Narishige, Japan) and plated into the RT buffer. Single HSC1 cells were cultured in serum-free media with SCF + TPO or SCF + TPO + TGF-β1 for 48 and 120 hr. One cell was picked from each of 48 wells by the micromanipulator and plated into the RT buffer. On the other hand, single HSC1 cells were cultured in serum-free media with SCF + TPO or SCF + TPO + TGF-β1 for 120 hr. In the case of the SCF + TPO culture, 48 single cells were picked from a colony consisting of 56 cells. In the case of SCF + TPO + TGF-β1, 8, 20, and 20 single cells were picked from colonies consisting of 8, 20, and 26 cells, respectively, and plated into the RT buffer.

Reverse transcription was performed at 50°C for 15 min. The samples were incubated at 95°C for 2 min, followed by 22 cycles of 95°C for 15 s and 60°C for 4 min. Five microliters, taken from the samples, was mixed with 20 μL of Tris-EDTA and was used for real-time PCR. Then, 2.7 μL, taken from the diluted samples, was mixed with 3.0 μL TaqMan universal PCR master mix (Applied Biosystems) and 0.3 μL of sample loading buffer (a total of 6.0 μL sample loading mix). On the other hand, 3.0 μL of each set of 20× primers was mixed with 3.0 μL of the assay loading reagent (a total of 6.0 μL assay loading mix). Then, 5 μL of the sample
loading and 5 μL of the assay loading mix were applied to a 48 chip, and 48 x 48 reactions were prepared by an integrated fluidic circuit controller. The chip was set on a Fluidigm Biomark system and was incubated at 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. The data were analyzed by Biomark real-time PCR analysis software (Fluidigm). The sets of PCR primers, as listed in Tables S1-S3, were purchased from Thermo Fisher Scientific (Peixoto et al., 2004).

Neutralization of TGF-β1
Anti-TGF-β1 neutralizing antibody (1D11) was purchased from R&D Systems. HSC1 cells were cultured in SCF + TPO + TGF-β1 (100 pg/mL) with different concentrations (0, 5, 50, and 500 ng/mL, and 5 μg/mL), and 500 ng/mL was found to block the negative effect of TGF-β1 sufficiently. Single HSC1 cells were cultured in SCF + TPO or SCF + TPO + TGF-β1 for 7 days. Anti-TGF-β1 neutralizing antibody was added at the concentration of 500 ng/mL to the culture on days 0, 1, 3, and 5.

Statistics
An unpaired t test was used to compare the means from two groups, and ANOVA was used to compare the means from three groups or more, using GraphPad Prism 5.0 (GraphPad) and SPSS 17.0 statistical software (IBM).

SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and three tables and can be found with this article online at https://doi.org/10.1016/j.stemcr.2018.05.017.

AUTHOR CONTRIBUTIONS
X.W. performed the experiments, analyzed the data, and wrote the manuscript. F.D., S.Z., Z.W., and Sh.Z. helped with the transplantation experiments. W.Y., W.Y., and S.M. helped with the single-cell gene expression analysis. J.W. helped with the flow cytometry operation. P.W., Y.G., J.D., and F.T. helped with data analysis. T.C. and H.E. directed the research programs, designed the study, and wrote the manuscript.

ACKNOWLEDGMENTS
We thank Drs. Caiying Zhu and Sha Hao for their assistance with the data analysis and our laboratory members for their support. This work was supported by grants from the Ministry of Science and Technology of China (2015CB964400), the National Key Research and Development Program of China Stem Cell and Translational Research (2017YFA0104903, 2016YFA0100600, and 2017YFA0103400), the CAMS Initiative for Innovative Medicine (2016-12M-1-017 and 2017-12M-1-015), and the National Natural Science Foundation of China (81470279, 81421002, 81670105, and 81500008).

Received: December 25, 2017
Revised: May 25, 2018
Accepted: May 25, 2018
Published: June 21, 2018

REFERENCES
Benz, C., Copley, M.R., Kent, D.G., Wohrer, S., Cortes, A., Aghaeepour, N., Ma, E., Mader, H., Rowe, K., Day, C., et al. (2012). Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 10, 273–283.

Bernitz, J.M., Kim, H.S., MacArthur, B., Sieburg, H., and Moore, K. (2016). Hematopoietic stem cell counts and remember self-renewal divisions. Cell 167, 1296–1309.e10.

Billing, M., Rorby, E., Dahl, M., Blank, U., Andradottir, S., Ehinger, M., and Karlsson, S. (2017). Signaling via Smad2 and Smad3 is dispensable for adult murine hematopoietic stem cell function in vivo. Exp. Hematol. 55, 34–44.e32.

Breinet, F., Kermani, P., Spektor, R., Rafii, S., and Scandura, J.M. (2013). TGFbeta restores hematopoietic homeostasis after myelo-suppressive chemotherapy. J. Exp. Med. 210, 623–639.

Carrelha, J., Meng, Y., Kettle, L.M., Luis, T.C., Norfo, R., Alcolea, V., Grasso, F., Gambardella, A., Grover, A., Hogstrand, K., et al. (2018). Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature 554, 106–111.

Challen, G.A., Boles, N.C., Chambers, S.M., and Goodell, M.A. (2010). Distinct hematopoietic stem cell subtypes are differentially regulated by Tgf-beta1. Cell Stem Cell 6, 265–278.

Cho, R.H., Sieburg, H.B., and Muller-Sieburg, C.E. (2008). A new mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood 111, 5553–5561.

Dybedal, I., Guan, F., Borge, O.J., Veiby, O.P., Rasmfjell, V., Nagata, S., and Jacobsen, S.E. (1997). Transforming growth factor-beta1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells. Blood 90, 3395–3403.

Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.J., Brinkman, R., and Eaves, C. (2007). Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 1, 218–229.

Ema, H., Morita, Y., and Suda, T. (2014). Heterogeneity and hierarchy of hematopoietic stem cells. Exp. Hematol. 42, 74–82.e72.

Ema, H., Sudo, K., Seita, J., Matsubara, A., Morita, Y., Osawa, M., Takatsu, K., Takaki, S., and Nakauchi, H. (2005). Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev. Cell 8, 907–914.

Ema, H., Takano, H., Sudo, K., and Nakauchi, H. (2000). In vitro self-renewal division of hematopoietic stem cells. J. Exp. Med. 192, 1281–1288.

Ieyasu, A., Ishida, R., Kimura, T., Morita, M., Wilkinson, A.C., Sudo, K., Nishimura, T., Ohehara, J., Tajima, Y., Lai, C.Y., et al. (2017). An all-recombinant protein-based culture system specifically identifies hematopoietic stem cell maintenance factors. Stem Cell Rep. 8, 500–508.

Jordan, C.T., and Lemischka, I.R. (1990). Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 4, 220–232.

Kale, V.P., and Vaidya, A.A. (2004). Molecular mechanisms behind the dose-dependent differential activation of MAPK pathways

286 Stem Cell Reports | Vol. 11 | 274–287 | July 10, 2018
induced by transforming growth factor-betalpha in hematopoietic cells. Stem Cells Dev. 13, 536–547.
Karlsson, G., Blank, U., Moody, J.L., Ehinger, M., Singhrant, S., Deng, C.X., and Karlsson, S. (2007). Smad4 is critical for self-renewal of hematopoietic stem cells. J. Exp. Med. 204, 467–474.
Larsson, J., Blank, U., Helgadottir, H., Bjornsson, J.M., Ehinger, M., Goumans, M.J., Fan, X., Levene, P., and Karlsson, S. (2003). TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood 102, 3129–3135.
Larsson, J., Blank, U., Klintman, J., Magnusson, M., and Karlsson, S. (2005). Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo. Exp. Hematol. 33, 592–596.
Larsson, J., and Karlsson, S. (2005). The role of Smad signaling in hematopoiesis. Oncogene 24, 5676–5692.
Massague, J. (1998). TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753–791.
Miyamoto, K., Araki, K.Y., Naka, K., Arai, F., Takubo, K., Yamazaki, S., Matsuoka, S., Miyamoto, K., Araki, F., Takubo, K., Yamazaki, S., Ohta, M., Greenberger, J.S., Anklesaria, P., Bassols, A., and Massague, J. (1987). Two forms of transforming growth factor-beta directly from hematopoietic stem cells. Cell 195, 709–720.
Pekars, E.M., Warr, M.R., and Passegue, E. (2011). Cell cycle regulation in hematopoietic stem cells. J. Cell Biol. 195, 709–720.
Saka, K., Lai, C.Y., Nojima, M., Kawahara, M., Otsu, M., Nakauchi, H., and Nagamune, T. (2017). Dissection of signaling events downstream of the c-Mpl receptor in murine hematopoietic stem cells via motif-engineered chimeric receptors. Stem Cell Rev. 14, 101–109.
Seita, J., and Weissman, I.L. (2010). Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 640–653.
Seoane, J., Le, H.V., Shen, L., Anderson, S.A., and Massague, J. (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211–223.
Shi, Y., and Massague, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685–700.
Sitnicka, E., Ruscetti, F.W., Priestley, G.V., Wolf, N.S., and Bartelmez, S.H. (1996). Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 88, 82–88.
Soma, T., Yu, J.M., and Dunbar, C.E. (1996). Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. Blood 87, 4561–4567.
Sun, J., Ramos, A., Chapman, B., Johnnidis, J.B., Le, L., Ho, Y.J., Klein, A., Hofmann, O., and Camargo, F.D. (2014). Clonal dynamics of native haematopoiesis. Nature 514, 322–327.
Dijke, P., and Hill, C.S. (2004). New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29, 265–273.
Tothova, Z., Kollipara, R., Huntly, B.J., Lee, B.H., Castrillon, D.H., Cullen, D.E., McDowell, E.P., Lazo-Kallanian, S., Williams, I.R., Sears, C., et al. (2007). FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128, 325–339.
Utsugisawa, T., Moody, J.L., Asplin, M., Nilsson, E., Carlsson, L., and Karlsson, S. (2006). A road map toward defining the role of Smad signaling in hematopoietic stem cells. Stem Cells 24, 1128–1136.
Wiesmann, A., Kim, M., Georgelas, A., Searles, A.E., Cooper, D.D., Green, W.F., and Spangrude, G.J. (2000). Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor beta. Exp. Hematol. 28, 128–139.
Yamamoto, R., Morita, Y., Ooehara, J., Hemanaka, S., Onodera, M., Rudolph, K.L., Ema, H., and Nakauchi, H. (2013). Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell 154, 1112–1126.
Yamazaki, S., Ema, H., Karlsson, G., Yamaguchi, T., Miyoshi, H., Shiota, S., Takeo, M.M., Karlsson, S., Iwama, A., and Nakauchi, H. (2011). Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147, 1146–1158.
Yamazaki, S., Iwama, A., Morita, Y., Eto, K., Ema, H., and Nakauchi, H. (2007). Cytokine signaling, lipid raft clustering, and HSC hibernation. Ann. N. Y Acad. Sci. 1106, 54–63.
Yamazaki, S., Iwama, A., Takayanagi, S., Eto, K., Ema, H., and Nakauchi, H. (2009). TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113, 1250–1256.
Zhao, M., Perry, J.M., Marshall, H., Venkatraman, A., Qian, P., He, X.C., Ahamed, J., and Li, L. (2014). Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat. Med. 20, 1321–1326.